Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · IEX Real-Time Price · USD
5.90
-0.15 (-2.48%)
At close: Apr 25, 2024, 4:00 PM
6.00
+0.10 (1.69%)
After-hours: Apr 25, 2024, 7:00 PM EDT
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for AMRX stock have an average target of 7.31, with a low estimate of 6.25 and a high estimate of 8.00. The average target predicts an increase of 23.90% from the current stock price of 5.90.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 21, 2024.
Analyst Ratings
The average analyst rating for AMRX stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $6 → $8 | Buy | Maintains | $6 → $8 | +35.59% | Mar 21, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $5.5 → $6.25 | Strong Buy | Maintains | $5.5 → $6.25 | +5.93% | Mar 4, 2024 |
| Barclays | Barclays | Buy Maintains $6 → $8 | Buy | Maintains | $6 → $8 | +35.59% | Jan 29, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $6 → $7 | Strong Buy | Maintains | $6 → $7 | +18.64% | Nov 8, 2023 |
| Truist Securities | Truist Securities | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +1.69% | Sep 6, 2023 |
Financial Forecast
Revenue This Year
2.66B
from 2.39B
Increased by 11.13%
Revenue Next Year
2.61B
from 2.66B
Decreased by -1.84%
EPS This Year
0.59
from -0.48
EPS Next Year
0.59
from 0.59
Decreased by -0.34%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 2.8B | 3.0B | 3.0B |
| Avg | 2.6B | 2.7B | 2.8B |
| Low | 2.5B | 2.5B | 2.5B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 16.0% | 13.1% | 11.9% |
| Avg | 9.1% | 3.7% | 4.0% |
| Low | 2.5% | -4.8% | -6.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.66 | 0.72 | 0.82 |
| Avg | 0.59 | 0.66 | 0.72 |
| Low | 0.53 | 0.58 | 0.63 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | 22.5% | 24.5% |
| Avg | - | 11.2% | 8.9% |
| Low | - | -2.3% | -4.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.